Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Myovant Sciences stock

MYOV
BMG637AM1024
A2DFYA

Price

26.98
Today +/-
+0
Today %
+0 %

Myovant Sciences stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Myovant Sciences stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Myovant Sciences stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Myovant Sciences stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Myovant Sciences's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Myovant Sciences Stock Price History

DateMyovant Sciences Price
3/8/202326.98 undefined
3/7/202326.99 undefined

Myovant Sciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Myovant Sciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Myovant Sciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Myovant Sciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Myovant Sciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Myovant Sciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Myovant Sciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Myovant Sciences’s growth potential.

Myovant Sciences Revenue, EBIT and net profit per share

DateMyovant Sciences RevenueMyovant Sciences EBITMyovant Sciences Net Income
2028e1.59 B undefined247.96 M undefined168.61 M undefined
2027e1.52 B undefined334.66 M undefined228.11 M undefined
2026e1.08 B undefined-2.14 M undefined93.22 M undefined
2025e701.44 M undefined47.51 M undefined-52.23 M undefined
2024e556.07 M undefined-43.94 M undefined-90.85 M undefined
2023e427.93 M undefined-100.91 M undefined-173.17 M undefined
2022230.97 M undefined-187.35 M undefined-205.98 M undefined
202159.32 M undefined-260.78 M undefined-255.13 M undefined
20200 undefined-274.89 M undefined-288.99 M undefined
20190 undefined-264.83 M undefined-273.55 M undefined
20180 undefined-141.06 M undefined-143.26 M undefined
20170 undefined-55.86 M undefined-83.44 M undefined
20160 undefined-1.66 M undefined-1.66 M undefined

Myovant Sciences Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20162017201820192020202120222023e2024e2025e2026e2027e2028e
000000.060.230.430.560.71.081.521.59
------289.8385.6530.2126.0854.3540.854.46
-----96.6177.8341.9232.1925.5316.5411.7511.24
0000057179000000
-1-83-143-273-288-255-205-173-90-5293228168
-8,200.0072.2990.915.49-11.46-19.61-15.61-47.98-42.22-278.85145.16-26.32
58.5249.1859.5266.9185.8490.0492.97000000
-------------
Details

Keystats

ⓘ

Revenue and Growth

The Myovant Sciences Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Myovant Sciences is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (k)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (B)TOTAL CAPITAL (M)
2016201720182019202020212022
             
0180.8108.6156.179.6684.9434.19
000003.623.3
000000580
000002.67.58
03.25.110.28.313.522.5
0184113.7166.387.9704.6488.15
00.91.32.113.61310.91
0000000
0000000
0000000
0000000
00.23.14.14.47.420.96
01.14.46.21820.431.87
0185.1118.1172.5105.9725520.01
             
0000002
1.4251.7266.2505.9684.4709.5795.94
-1.7-85.1-228.5-502-791-1,046.1-1,252.13
01000500-1,600-17,300-17,285
0000000
-0.3166.737.74.4-108.2-353.9-473.48
0.23.34.61115.317.812.25
01230.554.730.646.470.74
0320.140217.1167.34
0000000
0006.1000
0.218.337.171.985.9281.3250.33
0043.693.2113.7358.7358.7
0000000
00.20.73.414.6439384.46
00.244.396.6128.3797.7743.16
00.020.080.170.211.080.99
-0.1185.2119.1172.9106725.1520.01
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Myovant Sciences provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Myovant Sciences's financial health and stability.

Assets

Myovant Sciences's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Myovant Sciences must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Myovant Sciences after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Myovant Sciences's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2016201720182019202020212022
-1-83-143-273-289-255-205
0000121
0000000
015132717584-107
1491222483843
00031300
0000003
0-18-117-224-221370-268
0-10-1-1-10
0-10-1-3-9-18
0000-2-7-17
0000000
000082450
02021220137624
02004527314523825
0-243530-131
0000000
0180-7248-79599-260
0-19.2-117.9-225.3-222.3368.8-269.53
0000000

Myovant Sciences stock margins

The Myovant Sciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Myovant Sciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Myovant Sciences.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Myovant Sciences's sales revenue. A higher gross margin percentage indicates that the Myovant Sciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Myovant Sciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Myovant Sciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Myovant Sciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Myovant Sciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Myovant Sciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Myovant Sciences Margin History

Myovant Sciences Gross marginMyovant Sciences Profit marginMyovant Sciences EBIT marginMyovant Sciences Profit margin
2028e77.68 %15.57 %10.58 %
2027e77.68 %21.96 %14.97 %
2026e77.68 %-0.2 %8.62 %
2025e77.68 %6.77 %-7.45 %
2024e77.68 %-7.9 %-16.34 %
2023e77.68 %-23.58 %-40.47 %
202277.68 %-81.11 %-89.18 %
202196.68 %-439.62 %-430.09 %
202077.68 %0 %0 %
201977.68 %0 %0 %
201877.68 %0 %0 %
201777.68 %0 %0 %
201677.68 %0 %0 %

Myovant Sciences Stock Sales Revenue, EBIT, Earnings per Share

The Myovant Sciences earnings per share therefore indicates how much revenue Myovant Sciences has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Myovant Sciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Myovant Sciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Myovant Sciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Myovant Sciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Myovant Sciences Revenue, EBIT and net profit per share

DateMyovant Sciences Sales per ShareMyovant Sciences EBIT per shareMyovant Sciences Earnings per Share
2028e16.38 undefined0 undefined1.73 undefined
2027e15.67 undefined0 undefined2.35 undefined
2026e11.13 undefined0 undefined0.96 undefined
2025e7.21 undefined0 undefined-0.54 undefined
2024e5.72 undefined0 undefined-0.93 undefined
2023e4.4 undefined0 undefined-1.78 undefined
20222.48 undefined-2.02 undefined-2.22 undefined
20210.66 undefined-2.9 undefined-2.83 undefined
20200 undefined-3.2 undefined-3.37 undefined
20190 undefined-3.96 undefined-4.09 undefined
20180 undefined-2.37 undefined-2.41 undefined
20170 undefined-1.14 undefined-1.7 undefined
20160 undefined-0.03 undefined-0.03 undefined

Myovant Sciences business model

Myovant Sciences Ltd. is a biotech company based in London that specializes in medications for women and men in various therapy areas. The company was founded in 2016 through the collaboration of Takeda Pharmaceutical and Roivant Sciences Ltd. After going public in 2016, Myovant is now listed on the NYSE. Myovant Sciences focuses on medications for the treatment of reproductive system disorders, hormone regulation, and urinary tract issues in aging individuals. The company is involved in research and development of new therapy options and currently has a pipeline of 5 projects focusing on the following indications: - Symptomatic uterine fibroids - Endometriosis - Prostate cancer - Reproductive disorders in women - Reproductive disorders in men A fibroid is a growth in the tissue of the uterus that often occurs in women of reproductive age and becomes symptomatic. Endometriosis is a chronic, painful condition where tissue that normally lines the uterus grows outside of it. Myovant can also offer treatment options for reproductive disorders in men. The founders of Myovant Sciences aim to improve patient care, especially for rare diseases that are often under-researched and lack effective treatment options. The company focuses on innovative technologies and customized solutions to differentiate themselves from other companies. This includes a focus on targeted therapy options tailored to specific patient groups. Myovant has embraced the motto "Don't become MVP (Most Valuable Player), become MVP - Medical Value Provider." The company works closely with clinics, universities, research institutions, and other companies in the industry to leverage the latest scientific developments and use them for the development of medical solutions for the market. Myovant offers a wide range of products, with a main focus on medications for women and men with severe reproductive system, hormone, and urinary tract disorders in aging individuals. An example of a product is Elagolix, which was developed in collaboration with Abbvie Inc. for the treatment of endometriosis-related pain in women. Myovant Sciences Ltd. is an innovative company with an ambitious goal of developing medications for patients suffering from reproductive system disorders, hormone regulation, and urinary tract issues in aging individuals. The company conducts research and development of products for specific indications in order to offer targeted therapy options for patients. Myovant works closely with numerous partners to develop innovative solutions for patients. Myovant Sciences is one of the most popular companies on Eulerpool.com.

Myovant Sciences SWOT Analysis

Strengths

1. Strong pipeline of innovative products with potential for market-leading breakthroughs.

2. Strategic partnerships and collaborations with major pharmaceutical companies.

3. Experienced and talented management team with deep knowledge in the biopharmaceutical industry.

Weaknesses

1. Heavy reliance on successful clinical trials and regulatory approvals.

2. Limited financial resources compared to larger industry competitors.

3. Limited geographical presence, primarily operating within specific regions.

Opportunities

1. Growing demand for innovative treatment options in the healthcare sector.

2. Expansion into new geographic markets to increase market share.

3. Potential for partnerships and licensing deals to accelerate product development and commercialization.

Threats

1. Intense competition from existing pharmaceutical companies in the market.

2. Stringent regulatory environment and the risk of delays in product approvals.

3. Economic and political factors impacting the healthcare industry.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Myovant Sciences Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Myovant Sciences historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Myovant Sciences shares outstanding

The number of shares was Myovant Sciences in 2024 — This indicates how many shares 92.975 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Myovant Sciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Myovant Sciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Myovant Sciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Myovant Sciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Myovant Sciences.

Myovant Sciences latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
12/31/2022-0.48 -0.59  (-21.78 %)2023 Q3
9/30/2022-0.5 -0.47  (5.49 %)2023 Q2
6/30/2022-0.32 -0.22  (32.18 %)2023 Q1
3/31/2022-0.58 -0.63  (-7.99 %)2022 Q4
12/31/2021-0.63 -0.68  (-8.57 %)2022 Q3
9/30/2021-0.39 -0.23  (40.35 %)2022 Q2
6/30/2021-0.35 -0.67  (-93.19 %)2022 Q1
3/31/2021-1.01 -0.89  (12.28 %)2021 Q4
12/31/2020-0.87 -0.82  (5.42 %)2021 Q3
9/30/2020-0.75 -0.75  (0 %)2021 Q2
1
2
3

Myovant Sciences shareholders

%
Name
Stocks
Change
Date
47.10050 % Sumitomo Chemical Co Ltd45,798,176-4,243,0053/10/2023
8.86979 % Fidelity Investments Canada ULC8,624,5438,624,54312/31/2022
6.60779 % Alpine Global Management, LLC6,425,0845,888,4702/8/2023
6.07872 % Bellevue Asset Management AG5,910,639-2,00012/31/2022
5.24864 % Fidelity Institutional Asset Management5,103,5125,103,51212/31/2022
2.99277 % State Street Global Advisors (US)2,910,023893,66512/31/2022
2.41491 % Goldman Sachs & Company, Inc.2,348,1421,928,96712/31/2022
1.85658 % Carlson Capital, L.P.1,805,2491,805,24912/31/2022
1.42701 % AQR Capital Management, LLC1,387,5501,387,55012/31/2022
1.37608 % Highland Capital Management Fund Advisors, L.P.1,338,0301,338,03012/31/2022
1
2
3
4
5
...
10

Myovant Sciences Executives and Management Board

Mr. David Marek

(57)
Myovant Sciences Principal Executive Officer, Director (since 2021)
Compensation 6.25 M

Mr. Uneek Mehra

(50)
Myovant Sciences Chief Financial and Business Officer, Principal Financial and Accounting Officer
Compensation 5.16 M

Ms. Lauren Merendino

(47)
Myovant Sciences Chief Commercial Officer
Compensation 3.46 M

Mr. Matthew Lang

(46)
Myovant Sciences General Counsel, Corporate Secretary and Chief Legal and Administrative Officer and Corporate Secretary of Myovant Sciences, Inc.
Compensation 2.83 M

Dr. Juan Camilo Arjona Ferreira

(52)
Myovant Sciences Chief Medical Officer
Compensation 1.98 M
1
2
3

Most common questions regarding Myovant Sciences

What values and corporate philosophy does Myovant Sciences represent?

Myovant Sciences Ltd represents values of innovation, integrity, and collaboration in the biopharmaceutical industry. With a commitment to advancing women's health and prostate cancer treatments, Myovant Sciences focuses on developing novel therapies that address critical unmet medical needs. The company's corporate philosophy revolves around scientific excellence, patient-centricity, and responsible business practices. By combining cutting-edge research with a passion for making a difference, Myovant Sciences strives to improve the lives of patients globally. As a leader in the field, Myovant Sciences Ltd continues to push boundaries and shape the future of healthcare.

In which countries and regions is Myovant Sciences primarily present?

Myovant Sciences Ltd is primarily present in multiple countries and regions around the world. The company has a global presence, with a focus on regions such as the United States, Europe, and Asia. Their innovative approach and commitment to improving healthcare have allowed them to expand their operations internationally, reaching patients and healthcare professionals in various markets. With their extensive reach, Myovant Sciences Ltd continues to make significant contributions to the field of medicine and positively impact the lives of individuals across different countries and regions.

What significant milestones has the company Myovant Sciences achieved?

Myovant Sciences Ltd has achieved several significant milestones. In 2018, the company announced positive Phase 3 clinical trial results for relugolix, its lead product candidate for the treatment of uterine fibroids and endometriosis-associated pain. These results demonstrated the drug's efficacy and safety in reducing menstrual blood loss and alleviating pain. In 2020, Myovant Sciences received FDA approval for relugolix in the treatment of advanced prostate cancer. This marked a major breakthrough as it became the first and only oral gonadotropin-releasing hormone receptor antagonist approved by the FDA for this indication. Myovant Sciences continues to innovate and develop novel therapies to address unmet medical needs.

What is the history and background of the company Myovant Sciences?

Myovant Sciences Ltd is a biopharmaceutical company specializing in the development and commercialization of innovative therapies. Established in 2016, Myovant Sciences focuses on improving the lives of patients suffering from women's health and prostate cancer conditions. The company aims to address significant unmet medical needs through its proprietary product pipeline and strategic collaborations. Through their dedication to scientific advancement and patient-centric approach, Myovant Sciences aims to make a positive impact on the healthcare industry. With a strong focus on research and development, Myovant Sciences Ltd continues to strive towards bringing novel therapies to market to benefit patients worldwide.

Who are the main competitors of Myovant Sciences in the market?

Some of the main competitors of Myovant Sciences Ltd in the market include AbbVie Inc., TherapeuticsMD, and ObsEva SA.

In which industries is Myovant Sciences primarily active?

Myovant Sciences Ltd is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Myovant Sciences?

Myovant Sciences Ltd is a biopharmaceutical company that focuses on developing and commercializing innovative therapies for women's health and endocrine diseases. The company aims to address significant unmet medical needs with its cutting-edge research and drug development. Myovant Sciences utilizes strategic partnerships and collaborations to advance its pipeline of potential treatments. The company primarily focuses on areas such as uterine fibroids, endometriosis, and prostate cancer. By leveraging its expertise and research capabilities, Myovant Sciences is dedicated to improving the lives of patients and delivering value to its shareholders through its unique business model.

What is the P/E ratio of Myovant Sciences 2025?

The Myovant Sciences P/E ratio is -48.02.

What is the P/S ratio of Myovant Sciences 2025?

The Myovant Sciences P/S ratio is 3.58.

What is the Quality Investing of Myovant Sciences?

The Quality Investing for Myovant Sciences is 3/10.

What is the revenue of Myovant Sciences 2025?

The expected Myovant Sciences revenue is 701.44 M USD.

How high is the profit of Myovant Sciences 2025?

The expected Myovant Sciences profit is -52.23 M USD.

What is the business model of Myovant Sciences

Myovant Sciences Ltd is a biopharmaceutical company based in London that focuses on developing high-quality therapeutics for women and men. The company's business model is based on research and development of treatments for various medical conditions such as cancer, endometriosis, and infertility. They offer both preclinical and clinical development programs, working closely with renowned research institutions and medical experts to develop innovative solutions for patients, particularly focusing on hormone treatments. Myovant's product portfolio includes several products and medications in various stages of development, with one of the main products being Relugolix, which has shown promise in clinical studies for the treatment of cancer (prostate cancer), endometriosis, and uterine fibroids. It aims to reduce the growth rate of cancer cells by inhibiting certain hormones, potentially halting or even reversing the progression of the disease. Another substance, RVT-601, is currently being developed primarily for the treatment of bladder problems in women. Myovant Sciences operates in different markets and has distribution partners in Europe, USA, and Asia. The company's goal is to establish itself as a leading company in the field of hormone therapy and transform the healthcare industry as a whole. It focuses on therapies that regulate hormone balance and support the body's natural functions, particularly benefiting patients with congenital or hormone-related conditions. Additionally, Myovant is involved in initiatives to empower women within society, partnering and campaigning for equality, awareness, and access to healthcare services for women under the brand MyoEmpower. To conclude, Myovant Sciences Ltd is a promising company specializing in the development of high-quality therapeutics for women and men. Their strategic focus on hormone therapy and collaboration with renowned research institutions position them as industry innovators.

What is the Myovant Sciences dividend?

Myovant Sciences pays a dividend of 0 USD distributed over payouts per year.

How often does Myovant Sciences pay dividends?

The dividend cannot currently be calculated for Myovant Sciences or the company does not pay out a dividend.

What is the Myovant Sciences ISIN?

The ISIN of Myovant Sciences is BMG637AM1024.

What is the Myovant Sciences WKN?

The WKN of Myovant Sciences is A2DFYA.

What is the Myovant Sciences ticker?

The ticker of Myovant Sciences is MYOV.

How much dividend does Myovant Sciences pay?

Over the past 12 months, Myovant Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Myovant Sciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Myovant Sciences?

The current dividend yield of Myovant Sciences is .

When does Myovant Sciences pay dividends?

Myovant Sciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Myovant Sciences?

Myovant Sciences paid dividends every year for the past 0 years.

What is the dividend of Myovant Sciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Myovant Sciences located?

Myovant Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Myovant Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Myovant Sciences from 2/9/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 2/9/2025.

When did Myovant Sciences pay the last dividend?

The last dividend was paid out on 2/9/2025.

What was the dividend of Myovant Sciences in the year 2024?

In the year 2024, Myovant Sciences distributed 0 USD as dividends.

In which currency does Myovant Sciences pay out the dividend?

The dividends of Myovant Sciences are distributed in USD.

All fundamentals about Myovant Sciences

Our stock analysis for Myovant Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Myovant Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.